References
- BieloryLFriedlaenderMHAllergic conjunctivitisImmunol Allergy Clin North Am200828435818282545
- Bepotastine (Bepreve): an ophthalmic H1-antihistamineMed Lett Drugs Ther201052111220216525
- BieloryLOcular allergy treatmentImmunol Allergy Clin North Am20082818922418282552
- Physicians’ Desk Reference for Ophthalmic MedicinesMontvale, NJThomson Reuters2008282
- BartlettJDHowesJFGhormleyNRSafety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitisCurr Eye Res1993123133218319490
- DellSJLowryGMNorthcuttJAA randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitisJ Allergy Clin Immunol19981022512559723669
- DellSJShulmanDGLowryGMHowesJA controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study GroupAm J Ophthalmol19971237917979535623
- ShulmanDGLothringerLLRubinJMA randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitisOphthalmology19991063623699951491
- BergmanKBonapaceCClinical Pharmacology Review of Bepotastine Besilate Ophthalmic Solution 1.5%FDA2009
- HussarDAAbbasCANew drugs: asenapine, iloperidone, and bepotastine besilateJ Am Pharm Assoc (2003)20105010711020097650
- InomataNTatewakiSIkezawaZMultiple H1-antihistamine-induced urticariaJ Dermatol20093622422719348661
- KobayashiMKabashimaKNakamuraMTokuraYDownmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytesSkin Pharmacol Physiol200922454819088500
- KidaTFujiiASakaiOBepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis modelsExp Eye Res201091859120412793
- AbelsonABTorkildsenGLWilliamsJITime to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and childrenClin Ther2009311908192119843481
- MacejkoTTBergmannMTWilliamsJIMulticenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitisAm J Ophthalmol2010150122127.e5 Epub May 20, 2010.20488431
- RashidMWangYStatistical Review and Evaluation of Bepotastine Besilate Ophthalmic Solution 1.5% and 1.0% (Bepreve)FDA2009
- WadhwaSDClinical Review of Bepotastine Besilate Ophthalmic Solution 1.5%FDA2009
- TakahashiHIshida-YamamotoAIizukaHEffects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal- and flare-response, sedation, and psychomotor performanceClin Exp Dermatol20042952653215347340
- IzumiNMizuguchiHUmeharaHEvaluation of efficacy and sedative profiles of H(1) antihistamines by large-scale surveillance using the visual analogue scale (VAS)Allergol Int20085725726318566547